There is significant variability in the efficacy and safety of oral P2Y12 inhibitors, which are used to prevent ischemic outcomes in common diseases such as coronary and peripheral arterial disease ...

The results revealed that patients on P2Y12 inhibitors experienced a 23% lower risk of experiencing major cardiovascular events, including death from cardiovascular causes, heart attacks, and strokes, ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional ...

In patients who took a P2Y12 inhibitor, 58.7% received clopidogrel and 41.3% received ticagrelor. Over a median follow-up period of 1,351 days, MACCE—comprised of cardiovascular death, MI, or ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional ...

The researchers found that at a median follow-up of 1351 days, P2Y 12 inhibitor monotherapy was associated with a lower risk for MACCE vs aspirin monotherapy (one-stage analysis: hazard ratio, 0. ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

A major international study has found that heart patients, particularly seniors, may benefit more from newer blood-thinning medications called P2Y12 inhibitors than traditional aspirin therapy ...

P2Y12 inhibitors like ticagrelor and clopidogrel provide a 23% lower risk of heart-related death, heart attack or stroke compared to aspirin. The drugs work by making platelets less sticky, ...

For example, you may get nosebleeds and bruise more easily, ... P2Y12 inhibitor therapy was associated with a 23 per cent lower risk of an outcome that combined cardiovascular death, ...